[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 1, Issue 4 (Summer 2009) ::
IJBC 2009, 1(4): 129-137 Back to browse issues page
Safety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Seyed-Moayed Alavian *, Hassan Abolghasemi, Seyyed Mohammad Miri, Maryam Keshvari, Pegah Karimi Elizee, Bita Behnava, Seyed-Vahid Tabatabaei, Bashir Hajibeigi, Kamran Bagheri Lankarani
Abstract:   (14003 Views)

Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients.

Materials and Methods: A cohort of 51 HCV-RNA positive thalassemic patients were enrolled to our study and received 180 µg PEG-IFN A-2a once-weekly for 48 weeks. The primary end point was sustained virological response (SVR). The secondary outcome was normalization of ALT. Patient safety was assured by monthly, and if needed, weekly laboratory assessment and visits.

Results: Of 52 patients, 42 participants completed the treatment schedule. A sustained virological response (SVR) was attained in 22/51 (43%) cases. Among non-responders or relapsers to previous HCV antiviral therapy, 9/27 (33%) attained an SVR. Five patients died during treatment and 3 subjects discontinued the therapy because of adverse effects. Adverse events were generally mild, and laboratory abnormalities were rare.

Conclusion: A course of 48-week PEG-IFN A-2a monotherapy is effective in eradicating HCV-RNA during treatment. But about one third of thalassemic patients would relapse within 6 months of treatment schedule completion, in whom combination therapy is needed.

Keywords: Chronic hepatitis C, Thalassemia, Peginterferon alfa-2a
Full-Text [PDF 232 kb]   (4080 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Received: 2011/01/26 | Published: 2009/07/15
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alavian S, Abolghasemi H, Miri S M, Keshvari M, Karimi Elizee P, Behnava B, et al . Safety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia. IJBC 2009; 1 (4) :129-137
URL: http://ijbc.ir/article-1-2-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 1, Issue 4 (Summer 2009) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.05 seconds with 30 queries by YEKTAWEB 4509